• 29 Jul 2024
• Admin
• News Article

Sol-Gel Enters Six Exclusive License Agreements to Commercialize Twyneo and Epsolay

Sol-Gel enters six exclusive license agreements to commercialize Twyneo and Epsolay in Europe & South Africa

Overview

Sol-Gel Technologies, Ltd., a dermatology company, has entered into six (6) exclusive license agreements with MagnaPharm Trading Slovakia S.R.L, Galenica A.B, Leman SKL SA, InfectoPharm, Aspire Pharma Limited and Abex Pharmaceutica (PTY) Ltd. for the commercialization of Twyneo and Eposlay covering the majority of the European countries, including Germany, United Kingdom, France, Poland, Romania, Greece, Czech Republic, Sweden, Hungary, Austria, Switzerland, Serbia, Bulgaria, Finland, Slovakia, Norway, Croatia, Bosnia and Herzegovina, Albania, Lithuania, North Macedonia, Slovenia, Latvia, Estonia, Iceland, and South Africa. Under the terms of the agreements, Sol-Gel is to receive upfront and regulatory milestones payments totalling in up to low 7-digit USD as well as either future fixed transfer price or future low double digit royalties from net sales payments which are backed by commitments to minimum annual sales. The regulatory submissions in the various territories are the responsibility of Sol-Gel’s partners, and Sol-Gel will assist its partners in preparing these submissions.

Regarding Collaboration

These new collaborations are in addition to existing agreements that Sol-Gel has already signed in the US, Canada and China, emphasizing the trust and significant commercial potential for both drugs.

Words from CEO: Sol-Gel

• Alon Seri-Levy, Ph. D., chief executive officer of Sol-Gel, stated: "We are proud to deliver on our previous commitment to expand the territories in which Epsolay and Twyneo are available by signing these first six agreements in these new territories. This achievement marks the successful implementation of our goals, and we expect that more agreements will follow as we continue to expand and strengthen our position in these markets." 
• He further added that "We also see this as a vote of confidence in Sol-Gel's development and innovation capabilities. Our phase 3 trial of SGT-610 (patidegib gel, 2%) for the treatment of Gorlin syndrome is continuing, together with our clinical study for SGT-210 (topical erlotinib) for the treatment of Darier patients, and we believe that by meeting the trials’ endpoints, we will significantly further strengthen Sol-Gel's business and competitive position.”

About Epsolay Cream

• Epsolay is a topical cream containing benzoyl peroxide (BPO), 5%, for the treatment of bumps and blemishes (inflammatory lesions) of rosacea in adults. 
• Epsolay utilizes a proprietary, patented technology to encapsulate BPO within silica-based microcapsules to create a barrier between the medication and the skin. 
• The silica-based shell is designed to slowly release BPO over time to provide a tolerable and effective treatment.

Twyneo Cream

• Twyneo is a topical cream containing a fixed-dose combination of tretinoin, 0.1%, and benzoyl peroxide, 3%, cream for the treatment of acne vulgaris in adults and paediatric patients 9 years of age and older. 
• Twyneo is the first acne treatment that contains a fixed-dose combination of benzoyl peroxide and tretinoin. 
• Tretinoin and benzoyl peroxide are widely prescribed separately for acne vulgaris; however, benzoyl peroxide causes degradation of the tretinoin molecule, thereby potentially reducing its effectiveness if used at the same time or combined in the same formulation. 
• Twyneo uses silica (silicon dioxide) core shell structures to separately micro-encapsulate tretinoin crystals and benzoyl peroxide crystals enabling inclusion of the two active ingredients in the cream.

About Sol-Gel Technologies

• Sol-Gel Technologies, Ltd. is a dermatology company focused on identifying, developing and commercializing or partnering drug products to treat skin diseases. 
• Sol-Gel developed Twyneo which is approved by the FDA for the treatment of acne vulgaris in adults and paediatric patients nine years of age and older; and Epsolay, which is approved by the FDA for the treatment of inflammatory lesions of rosacea in adults.